UPDATE: Stifel Starts Obalon Therapeutics (OBLN) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Dollar sags after US GDP and inflation surprise, except against yen
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
UPDATE: UBS Starts Obalon Therapeutics (OBLN) at Buy
October 31, 2016 7:55 AM EDT(Updated - October 31, 2016 10:43 AM EDT)
UBS initiated coverage on Obalon Therapeutics (NASDAQ: OBLN) with a Buy rating and a price target of $21.
Analyst Matt Miksic said, "We are initiating coverage with a Buy rating and $21 target. We think Obalon's FDA PMA indication and... More
Canaccord Genuity Starts Obalon Therapeutics (OBLN) at Buy
October 31, 2016 7:54 AM EDTCanaccord Genuity initiated coverage on Obalon Therapeutics (NASDAQ: OBLN) with a Buy rating and a price target of $17.00.
For an analyst ratings summary and ratings history on Obalon Therapeutics click here. For more ratings news on Obalon Therapeutics click here.
Shares of Obalon Therapeutics closed at $13.80 yesterday.
... MoreBTIG Starts Obalon Therapeutics (OBLN) at Buy
October 31, 2016 7:53 AM EDTBTIG initiated coverage on Obalon Therapeutics (NASDAQ: OBLN) with a Buy rating and a price target of $20.
Analyst Sean Lavin said, "The obesity market is huge and growing. Technologies, surgeries, and pharmaceuticals prior to intragastric balloons have either been ineffective, unsafe, too... More
